<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240728041101&amp;utm_source=Chrome&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240728041101&amp;utm_source=Chrome&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Sun, 28 Jul 2024 08:11:03 +0000</lastbuilddate>
<pubDate>Fri, 26 Jul 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Natural malaria infection elicits rare but potent neutralizing antibodies to the blood-stage antigen RH5</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39059381/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240728041101&amp;v=2.18.0.post9+e462414
      <description>Plasmodium falciparum reticulocyte-binding protein homolog 5 (RH5) is the most advanced blood-stage malaria vaccine candidate and is being evaluated for efficacy in endemic regions, emphasizing the need to study the underlying antibody response to RH5 during natural infection, which could augment or counteract responses to vaccination. Here, we found that RH5-reactive B cells were rare, and circulating immunoglobulin G (IgG) responses to RH5 were short-lived in malaria-exposed Malian...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jul 17:S0092-8674(24)00711-6. doi: 10.1016/j.cell.2024.06.037. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Plasmodium falciparum reticulocyte-binding protein homolog 5 (RH5) is the most advanced blood-stage malaria vaccine candidate and is being evaluated for efficacy in endemic regions, emphasizing the need to study the underlying antibody response to RH5 during natural infection, which could augment or counteract responses to vaccination. Here, we found that RH5-reactive B cells were rare, and circulating immunoglobulin G (IgG) responses to RH5 were short-lived in malaria-exposed Malian individuals, despite repeated infections over multiple years. RH5-specific monoclonal antibodies isolated from eight malaria-exposed individuals mostly targeted non-neutralizing epitopes, in contrast to antibodies isolated from five RH5-vaccinated, malaria-naive UK individuals. However, MAD8-151 and MAD8-502, isolated from two malaria-exposed Malian individuals, were among the most potent neutralizers out of 186 antibodies from both cohorts and targeted the same epitopes as the most potent vaccine-induced antibodies. These results suggest that natural malaria infection may boost RH5-vaccine-induced responses and provide a clear strategy for the development of next-generation RH5 vaccines.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39059381/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240728041101&v=2.18.0.post9+e462414">39059381</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.06.037>10.1016/j.cell.2024.06.037</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39059381</guid>
<pubDate>Fri, 26 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Lawrence T Wang</dc:creator>
<dc:creator>Andrew J R Cooper</dc:creator>
<dc:creator>Brendan Farrell</dc:creator>
<dc:creator>Kazutoyo Miura</dc:creator>
<dc:creator>Ababacar Diouf</dc:creator>
<dc:creator>Nicole Müller-Sienerth</dc:creator>
<dc:creator>Cécile Crosnier</dc:creator>
<dc:creator>Lauren Purser</dc:creator>
<dc:creator>Payton J Kirtley</dc:creator>
<dc:creator>Maciej Maciuszek</dc:creator>
<dc:creator>Jordan R Barrett</dc:creator>
<dc:creator>Kirsty McHugh</dc:creator>
<dc:creator>Rodney Ogwang</dc:creator>
<dc:creator>Courtney Tucker</dc:creator>
<dc:creator>Shanping Li</dc:creator>
<dc:creator>Safiatou Doumbo</dc:creator>
<dc:creator>Didier Doumtabe</dc:creator>
<dc:creator>Chul-Woo Pyo</dc:creator>
<dc:creator>Jeff Skinner</dc:creator>
<dc:creator>Carolyn M Nielsen</dc:creator>
<dc:creator>Sarah E Silk</dc:creator>
<dc:creator>Kassoum Kayentao</dc:creator>
<dc:creator>Aissata Ongoiba</dc:creator>
<dc:creator>Ming Zhao</dc:creator>
<dc:creator>Doan C Nguyen</dc:creator>
<dc:creator>F Eun-Hyung Lee</dc:creator>
<dc:creator>Angela M Minassian</dc:creator>
<dc:creator>Daniel E Geraghty</dc:creator>
<dc:creator>Boubacar Traore</dc:creator>
<dc:creator>Robert A Seder</dc:creator>
<dc:creator>Brandon K Wilder</dc:creator>
<dc:creator>Peter D Crompton</dc:creator>
<dc:creator>Gavin J Wright</dc:creator>
<dc:creator>Carole A Long</dc:creator>
<dc:creator>Simon J Draper</dc:creator>
<dc:creator>Matthew K Higgins</dc:creator>
<dc:creator>Joshua Tan</dc:creator>
<dc:date>2024-07-26</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Natural malaria infection elicits rare but potent neutralizing antibodies to the blood-stage antigen RH5</dc:title>
<dc:identifier>pmid:39059381</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.06.037</dc:identifier>
</item>
<item>
<title>Analysis of the diverse antigenic landscape of the malaria protein RH5 identifies a potent vaccine-induced human public antibody clonotype</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39059380/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240728041101&amp;v=2.18.0.post9+e462414
      <description>The highly conserved and essential Plasmodium falciparum reticulocyte-binding protein homolog 5 (PfRH5) has emerged as the leading target for vaccines against the disease-causing blood stage of malaria. However, the features of the human vaccine-induced antibody response that confer highly potent inhibition of malaria parasite invasion into red blood cells are not well defined. Here, we characterize 236 human IgG monoclonal antibodies, derived from 15 donors, induced by the most advanced PfRH5...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jul 18:S0092-8674(24)00655-X. doi: 10.1016/j.cell.2024.06.015. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The highly conserved and essential Plasmodium falciparum reticulocyte-binding protein homolog 5 (PfRH5) has emerged as the leading target for vaccines against the disease-causing blood stage of malaria. However, the features of the human vaccine-induced antibody response that confer highly potent inhibition of malaria parasite invasion into red blood cells are not well defined. Here, we characterize 236 human IgG monoclonal antibodies, derived from 15 donors, induced by the most advanced PfRH5 vaccine. We define the antigenic landscape of this molecule and establish that epitope specificity, antibody association rate, and intra-PfRH5 antibody interactions are key determinants of functional anti-parasitic potency. In addition, we identify a germline IgG gene combination that results in an exceptionally potent class of antibody and demonstrate its prophylactic potential to protect against P. falciparum parasite challenge in vivo. This comprehensive dataset provides a framework to guide rational design of next-generation vaccines and prophylactic antibodies to protect against blood-stage malaria.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39059380/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240728041101&v=2.18.0.post9+e462414">39059380</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.06.015>10.1016/j.cell.2024.06.015</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39059380</guid>
<pubDate>Fri, 26 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Jordan R Barrett</dc:creator>
<dc:creator>Dimitra Pipini</dc:creator>
<dc:creator>Nathan D Wright</dc:creator>
<dc:creator>Andrew J R Cooper</dc:creator>
<dc:creator>Giacomo Gorini</dc:creator>
<dc:creator>Doris Quinkert</dc:creator>
<dc:creator>Amelia M Lias</dc:creator>
<dc:creator>Hannah Davies</dc:creator>
<dc:creator>Cassandra A Rigby</dc:creator>
<dc:creator>Maya Aleshnick</dc:creator>
<dc:creator>Barnabas G Williams</dc:creator>
<dc:creator>William J Bradshaw</dc:creator>
<dc:creator>Neil G Paterson</dc:creator>
<dc:creator>Thomas Martinson</dc:creator>
<dc:creator>Payton Kirtley</dc:creator>
<dc:creator>Luc Picard</dc:creator>
<dc:creator>Christine D Wiggins</dc:creator>
<dc:creator>Francesca R Donnellan</dc:creator>
<dc:creator>Lloyd D W King</dc:creator>
<dc:creator>Lawrence T Wang</dc:creator>
<dc:creator>Jonathan F Popplewell</dc:creator>
<dc:creator>Sarah E Silk</dc:creator>
<dc:creator>Jed de Ruiter Swain</dc:creator>
<dc:creator>Katherine Skinner</dc:creator>
<dc:creator>Vinayaka Kotraiah</dc:creator>
<dc:creator>Amy R Noe</dc:creator>
<dc:creator>Randall S MacGill</dc:creator>
<dc:creator>C Richter King</dc:creator>
<dc:creator>Ashley J Birkett</dc:creator>
<dc:creator>Lorraine A Soisson</dc:creator>
<dc:creator>Angela M Minassian</dc:creator>
<dc:creator>Douglas A Lauffenburger</dc:creator>
<dc:creator>Kazutoyo Miura</dc:creator>
<dc:creator>Carole A Long</dc:creator>
<dc:creator>Brandon K Wilder</dc:creator>
<dc:creator>Lizbé Koekemoer</dc:creator>
<dc:creator>Joshua Tan</dc:creator>
<dc:creator>Carolyn M Nielsen</dc:creator>
<dc:creator>Kirsty McHugh</dc:creator>
<dc:creator>Simon J Draper</dc:creator>
<dc:date>2024-07-26</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Analysis of the diverse antigenic landscape of the malaria protein RH5 identifies a potent vaccine-induced human public antibody clonotype</dc:title>
<dc:identifier>pmid:39059380</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.06.015</dc:identifier>
</item>
<item>
<title>"Boosting" tumor immunity in elderly mice by hyperactivating dendritic cells</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39059365/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240728041101&amp;v=2.18.0.post9+e462414
      <description>Immunosenescence poses a significant challenge to tumor immunotherapy in elderly individuals. In this issue of Cell, Zhivaki et al. elucidate that dendritic cells "hyperactivated" by specific adjuvants elicit T(H)1-skewed CD4^(+) T cell responses in a manner contingent on the NLRP3 inflammasome, which can eliminate tumors in aged mice.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jul 25;187(15):3885-3887. doi: 10.1016/j.cell.2024.06.025.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Immunosenescence poses a significant challenge to tumor immunotherapy in elderly individuals. In this issue of Cell, Zhivaki et al. elucidate that dendritic cells "hyperactivated" by specific adjuvants elicit T<sub>H</sub>1-skewed CD4<sup>+</sup> T cell responses in a manner contingent on the NLRP3 inflammasome, which can eliminate tumors in aged mice.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39059365/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240728041101&v=2.18.0.post9+e462414">39059365</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.06.025>10.1016/j.cell.2024.06.025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39059365</guid>
<pubDate>Fri, 26 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Jiaqi Liu</dc:creator>
<dc:creator>Feng Shao</dc:creator>
<dc:date>2024-07-26</dc:date>
<dc:source>Cell</dc:source>
<dc:title>"Boosting" tumor immunity in elderly mice by hyperactivating dendritic cells</dc:title>
<dc:identifier>pmid:39059365</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.06.025</dc:identifier>
</item>
<item>
<title>Translating metabolic and cardiovascular research into effective treatments: What's next?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39059364/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240728041101&amp;v=2.18.0.post9+e462414
      <description>The future of healthcare for cardiovascular diseases holds immense promise, not only based in new discoveries in cardiac metabolism but also in translating them to solutions for critical challenges faced by society. Here, ten scientists share their insights, shedding light on the future that lies ahead for this field.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jul 25;187(15):3880-3884. doi: 10.1016/j.cell.2024.06.034.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The future of healthcare for cardiovascular diseases holds immense promise, not only based in new discoveries in cardiac metabolism but also in translating them to solutions for critical challenges faced by society. Here, ten scientists share their insights, shedding light on the future that lies ahead for this field.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39059364/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240728041101&v=2.18.0.post9+e462414">39059364</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.06.034>10.1016/j.cell.2024.06.034</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39059364</guid>
<pubDate>Fri, 26 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Juleen R Zierath</dc:creator>
<dc:creator>Jolanda van der Velden</dc:creator>
<dc:creator>Ali Javaheri</dc:creator>
<dc:creator>Anthony Rosenzweig</dc:creator>
<dc:creator>Deborah M Muoio</dc:creator>
<dc:creator>Erin E Mulvihill</dc:creator>
<dc:creator>Tami A Martino</dc:creator>
<dc:creator>Adil Rasheed</dc:creator>
<dc:creator>Xiao-Wei Chen</dc:creator>
<dc:creator>Zoltan P Arany</dc:creator>
<dc:date>2024-07-26</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Translating metabolic and cardiovascular research into effective treatments: What's next?</dc:title>
<dc:identifier>pmid:39059364</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.06.034</dc:identifier>
</item>
<item>
<title>Metabolism in the spotlight: Dr. Giles Yeo on the impact and challenges of science communication</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39059363/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240728041101&amp;v=2.18.0.post9+e462414
      <description>In this interview with Cell, Dr. Giles Yeo shares his journey into metabolism research, his strategies for engaging audiences, and the challenges of simplifying complex concepts. He also discusses the impact of social media, the advantages of podcasting, and the question he's most afraid of.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jul 25;187(15):3877-3879. doi: 10.1016/j.cell.2024.05.049.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">In this interview with Cell, Dr. Giles Yeo shares his journey into metabolism research, his strategies for engaging audiences, and the challenges of simplifying complex concepts. He also discusses the impact of social media, the advantages of podcasting, and the question he's most afraid of.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39059363/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240728041101&v=2.18.0.post9+e462414">39059363</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.05.049>10.1016/j.cell.2024.05.049</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39059363</guid>
<pubDate>Fri, 26 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Giles S H Yeo</dc:creator>
<dc:date>2024-07-26</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Metabolism in the spotlight: Dr. Giles Yeo on the impact and challenges of science communication</dc:title>
<dc:identifier>pmid:39059363</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.05.049</dc:identifier>
</item>
<item>
<title>Digesting the complex metabolic effects of diet on the host and microbiome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39059362/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240728041101&amp;v=2.18.0.post9+e462414
      <description>The past 50 years of interdisciplinary research in humans and model organisms has delivered unprecedented insights into the mechanisms through which diet affects energy balance. However, translating these results to prevent and treat obesity and its associated diseases remains challenging. Given the vast scope of this literature, we focus this Review on recent conceptual advances in molecular nutrition targeting the management of energy balance, including emerging dietary and pharmaceutical...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jul 25;187(15):3857-3876. doi: 10.1016/j.cell.2024.06.032.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The past 50 years of interdisciplinary research in humans and model organisms has delivered unprecedented insights into the mechanisms through which diet affects energy balance. However, translating these results to prevent and treat obesity and its associated diseases remains challenging. Given the vast scope of this literature, we focus this Review on recent conceptual advances in molecular nutrition targeting the management of energy balance, including emerging dietary and pharmaceutical interventions and their interactions with the human gut microbiome. Notably, multiple current dietary patterns of interest embrace moderate-to-high fat intake or prioritize the timing of eating over macronutrient intake. Furthermore, the rapid expansion of microbiome research findings has complicated multiple longstanding tenets of nutrition while also providing new opportunities for intervention. Continued progress promises more precise and reliable dietary recommendations that leverage our growing knowledge of the microbiome, the changing landscape of clinical interventions, and our molecular understanding of human biology.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39059362/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240728041101&v=2.18.0.post9+e462414">39059362</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.06.032>10.1016/j.cell.2024.06.032</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39059362</guid>
<pubDate>Fri, 26 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Rachel N Carmody</dc:creator>
<dc:creator>Krista Varady</dc:creator>
<dc:creator>Peter J Turnbaugh</dc:creator>
<dc:date>2024-07-26</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Digesting the complex metabolic effects of diet on the host and microbiome</dc:title>
<dc:identifier>pmid:39059362</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.06.032</dc:identifier>
</item>
<item>
<title>A metabolic balance of GLP-1 and NMDA receptors in the brain</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39059361/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240728041101&amp;v=2.18.0.post9+e462414
      <description>Glucagon-like peptide-1 (GLP-1) and N-methyl-D-aspartate (NMDA) receptors in the brain regulate metabolic homeostasis. In a paper published in Nature, Petersen et al. describe a bimodal molecule that conjugates a GLP-1 analog with MK-801 (NMDA receptor antagonist), which lowers feeding and body weight to a greater extent than the GLP-1R agonist alone.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jul 25;187(15):3854-3856. doi: 10.1016/j.cell.2024.06.031.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Glucagon-like peptide-1 (GLP-1) and N-methyl-D-aspartate (NMDA) receptors in the brain regulate metabolic homeostasis. In a paper published in Nature, Petersen et al. describe a bimodal molecule that conjugates a GLP-1 analog with MK-801 (NMDA receptor antagonist), which lowers feeding and body weight to a greater extent than the GLP-1R agonist alone.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39059361/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240728041101&v=2.18.0.post9+e462414">39059361</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.06.031>10.1016/j.cell.2024.06.031</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39059361</guid>
<pubDate>Fri, 26 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Jessica T Y Yue</dc:creator>
<dc:creator>Ameth N Garrido</dc:creator>
<dc:creator>Tony K T Lam</dc:creator>
<dc:date>2024-07-26</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A metabolic balance of GLP-1 and NMDA receptors in the brain</dc:title>
<dc:identifier>pmid:39059361</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.06.031</dc:identifier>
</item>
<item>
<title>Transforming obesity: The advancement of multi-receptor drugs</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39059360/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240728041101&amp;v=2.18.0.post9+e462414
      <description>For more than a century, physicians have searched for ways to pharmacologically reduce excess body fat. The tide has finally turned with recent advances in biochemically engineered agonists for the receptor of glucagon-like peptide-1 (GLP-1) and their use in GLP-1-based polyagonists. These polyagonists reduce body weight through complementary pharmacology by incorporating the receptors for glucagon and/or the glucose-dependent insulinotropic polypeptide (GIP). In their most advanced forms,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jul 25;187(15):3829-3853. doi: 10.1016/j.cell.2024.06.003.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">For more than a century, physicians have searched for ways to pharmacologically reduce excess body fat. The tide has finally turned with recent advances in biochemically engineered agonists for the receptor of glucagon-like peptide-1 (GLP-1) and their use in GLP-1-based polyagonists. These polyagonists reduce body weight through complementary pharmacology by incorporating the receptors for glucagon and/or the glucose-dependent insulinotropic polypeptide (GIP). In their most advanced forms, gut-hormone polyagonists achieve an unprecedented weight reduction of up to ∼20%-30%, offering a pharmacological alternative to bariatric surgery. Along with favorable effects on glycemia, fatty liver, and kidney disease, they also offer beneficial effects on the cardiovascular system and adipose tissue. These new interventions, therefore, hold great promise for the future of anti-obesity medications.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39059360/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240728041101&v=2.18.0.post9+e462414">39059360</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.06.003>10.1016/j.cell.2024.06.003</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39059360</guid>
<pubDate>Fri, 26 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Christine M Kusminski</dc:creator>
<dc:creator>Diego Perez-Tilve</dc:creator>
<dc:creator>Timo D Müller</dc:creator>
<dc:creator>Richard D DiMarchi</dc:creator>
<dc:creator>Matthias H Tschöp</dc:creator>
<dc:creator>Philipp E Scherer</dc:creator>
<dc:date>2024-07-26</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Transforming obesity: The advancement of multi-receptor drugs</dc:title>
<dc:identifier>pmid:39059360</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.06.003</dc:identifier>
</item>
<item>
<title>100 years of the Warburg effect: A cancer metabolism endeavor</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39059359/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240728041101&amp;v=2.18.0.post9+e462414
      <description>If you are a scientist and you only know one thing about tumor metabolism, it's likely the Warburg effect. But who was Otto Warburg, and how did his discoveries regarding the metabolism of tumors shape our current thinking about the metabolic needs of cancer cells?</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jul 25;187(15):3824-3828. doi: 10.1016/j.cell.2024.06.026.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">If you are a scientist and you only know one thing about tumor metabolism, it's likely the Warburg effect. But who was Otto Warburg, and how did his discoveries regarding the metabolism of tumors shape our current thinking about the metabolic needs of cancer cells?</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39059359/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240728041101&v=2.18.0.post9+e462414">39059359</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.06.026>10.1016/j.cell.2024.06.026</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39059359</guid>
<pubDate>Fri, 26 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Sarah-Maria Fendt</dc:creator>
<dc:date>2024-07-26</dc:date>
<dc:source>Cell</dc:source>
<dc:title>100 years of the Warburg effect: A cancer metabolism endeavor</dc:title>
<dc:identifier>pmid:39059359</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.06.026</dc:identifier>
</item>
<item>
<title>Metabolic heterogeneity in humans</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39059358/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240728041101&amp;v=2.18.0.post9+e462414
      <description>Recent advancements in technology, especially the emergence of single-cell technologies, genomic sequencing, metabolomics, and artificial intelligence, have enabled us to understand the distinct metabolic changes in different cell types, tissues, genders, disease states, ages, and populations. Six scientists whose work intersects with metabolism in various capacities tell us about their vision for human metabolic heterogeneity.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jul 25;187(15):3821-3823. doi: 10.1016/j.cell.2024.06.033.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Recent advancements in technology, especially the emergence of single-cell technologies, genomic sequencing, metabolomics, and artificial intelligence, have enabled us to understand the distinct metabolic changes in different cell types, tissues, genders, disease states, ages, and populations. Six scientists whose work intersects with metabolism in various capacities tell us about their vision for human metabolic heterogeneity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39059358/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240728041101&v=2.18.0.post9+e462414">39059358</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.06.033>10.1016/j.cell.2024.06.033</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39059358</guid>
<pubDate>Fri, 26 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Heather Christofk</dc:creator>
<dc:creator>Christian Metallo</dc:creator>
<dc:creator>Guanghui Liu</dc:creator>
<dc:creator>Joshua Rabinowitz</dc:creator>
<dc:creator>Lauren Sparks</dc:creator>
<dc:creator>David James</dc:creator>
<dc:date>2024-07-26</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Metabolic heterogeneity in humans</dc:title>
<dc:identifier>pmid:39059358</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.06.033</dc:identifier>
</item>
<item>
<title>Diabetes mellitus-Progress and opportunities in the evolving epidemic</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39059357/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240728041101&amp;v=2.18.0.post9+e462414
      <description>Diabetes, a complex multisystem metabolic disorder characterized by hyperglycemia, leads to complications that reduce quality of life and increase mortality. Diabetes pathophysiology includes dysfunction of beta cells, adipose tissue, skeletal muscle, and liver. Type 1 diabetes (T1D) results from immune-mediated beta cell destruction. The more prevalent type 2 diabetes (T2D) is a heterogeneous disorder characterized by varying degrees of beta cell dysfunction in concert with insulin resistance....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jul 25;187(15):3789-3820. doi: 10.1016/j.cell.2024.06.029.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Diabetes, a complex multisystem metabolic disorder characterized by hyperglycemia, leads to complications that reduce quality of life and increase mortality. Diabetes pathophysiology includes dysfunction of beta cells, adipose tissue, skeletal muscle, and liver. Type 1 diabetes (T1D) results from immune-mediated beta cell destruction. The more prevalent type 2 diabetes (T2D) is a heterogeneous disorder characterized by varying degrees of beta cell dysfunction in concert with insulin resistance. The strong association between obesity and T2D involves pathways regulated by the central nervous system governing food intake and energy expenditure, integrating inputs from peripheral organs and the environment. The risk of developing diabetes or its complications represents interactions between genetic susceptibility and environmental factors, including the availability of nutritious food and other social determinants of health. This perspective reviews recent advances in understanding the pathophysiology and treatment of diabetes and its complications, which could alter the course of this prevalent disorder.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39059357/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240728041101&v=2.18.0.post9+e462414">39059357</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.06.029>10.1016/j.cell.2024.06.029</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39059357</guid>
<pubDate>Fri, 26 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>E Dale Abel</dc:creator>
<dc:creator>Anna L Gloyn</dc:creator>
<dc:creator>Carmella Evans-Molina</dc:creator>
<dc:creator>Joshua J Joseph</dc:creator>
<dc:creator>Shivani Misra</dc:creator>
<dc:creator>Utpal B Pajvani</dc:creator>
<dc:creator>Judith Simcox</dc:creator>
<dc:creator>Katalin Susztak</dc:creator>
<dc:creator>Daniel J Drucker</dc:creator>
<dc:date>2024-07-26</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Diabetes mellitus-Progress and opportunities in the evolving epidemic</dc:title>
<dc:identifier>pmid:39059357</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.06.029</dc:identifier>
</item>
<item>
<title>50 years of metabolism research at Cell</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39059356/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240728041101&amp;v=2.18.0.post9+e462414
      <description>This 50th Anniversary Focus on Metabolism highlights several foundational and current themes of interest in metabolism research.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jul 25;187(15):3787-3788. doi: 10.1016/j.cell.2024.06.040.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">This 50th Anniversary Focus on Metabolism highlights several foundational and current themes of interest in metabolism research.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39059356/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240728041101&v=2.18.0.post9+e462414">39059356</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.06.040>10.1016/j.cell.2024.06.040</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39059356</guid>
<pubDate>Fri, 26 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Cell editorial team</dc:creator>
<dc:date>2024-07-26</dc:date>
<dc:source>Cell</dc:source>
<dc:title>50 years of metabolism research at Cell</dc:title>
<dc:identifier>pmid:39059356</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.06.040</dc:identifier>
</item>
<item>
<title>Post-capillary pulmonary hypertension in heart failure: impact of current definition in the PH-HF multicentre study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39056467/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240728041101&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This study is the first emphasizing the impact of the new pcPH definition on CpcPH prevalence and validating the prognostic value of mPAP >; 20 mmHg and PVR >; 2 WU among HF patients.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 26:ehae467. doi: 10.1093/eurheartj/ehae467. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Based on retrospective studies, the 2022 European guidelines changed the definition of post-capillary pulmonary hypertension (pcPH) in heart failure (HF) by lowering the level of mean pulmonary artery pressure (mPAP) and pulmonary vascular resistance (PVR). However, the impact of this definition and its prognostic value has never been evaluated prospectively.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Stable left HF patients with the need for right heart catheterization were enrolled from 2010 to 2018 and prospectively followed up in this multicentre study. The impact of the successive pcPH definitions on pcPH prevalence and subgroup [i.e. isolated (IpcPH) vs. combined pcPH (CpcPH)] was evaluated. Multivariable Cox regression analysis was used to assess the prognostic value of mPAP and PVR on all-cause death or hospitalization for HF (primary outcome).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Included were 662 HF patients were (median age 63 years, 60% male). Lowering mPAP from 25 to 20 mmHg resulted in +10% increase in pcPH prevalence, whereas lowering PVR from 3 to 2 resulted in +60% increase in CpcPH prevalence (with significant net reclassification improvement for the primary outcome). In multivariable analysis, both mPAP and PVR remained associated with the primary outcome [hazard ratio (HR) 1.02, 95% confidence interval (CI) 1.00-1.03, P = .01; HR 1.07, 95% CI 1.00-1.14, P = .03]. The best PVR threshold associated with the primary outcome was around 2.2 WU. Using the 2022 definition, pcPH patients had worse survival compared with HF patients without pcPH (log-rank, P = .02) as well as CpcPH compared with IpcPH (log-rank, P = .003).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study is the first emphasizing the impact of the new pcPH definition on CpcPH prevalence and validating the prognostic value of mPAP >; 20 mmHg and PVR >; 2 WU among HF patients.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39056467/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240728041101&v=2.18.0.post9+e462414">39056467</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae467>10.1093/eurheartj/ehae467</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39056467</guid>
<pubDate>Fri, 26 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Charles Fauvel</dc:creator>
<dc:creator>Thibaud Damy</dc:creator>
<dc:creator>Emmanuelle Berthelot</dc:creator>
<dc:creator>Fabrice Bauer</dc:creator>
<dc:creator>Jean-Christophe Eicher</dc:creator>
<dc:creator>Pascal de Groote</dc:creator>
<dc:creator>Jean-Noël Trochu</dc:creator>
<dc:creator>François Picard</dc:creator>
<dc:creator>Sébastien Renard</dc:creator>
<dc:creator>Hélène Bouvaist</dc:creator>
<dc:creator>Damien Logeart</dc:creator>
<dc:creator>François Roubille</dc:creator>
<dc:creator>Olivier Sitbon</dc:creator>
<dc:creator>Nicolas Lamblin</dc:creator>
<dc:date>2024-07-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Post-capillary pulmonary hypertension in heart failure: impact of current definition in the PH-HF multicentre study</dc:title>
<dc:identifier>pmid:39056467</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae467</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: apolipoprotein A1 is not an adequate shield against early vascular events after acute myocardial infarction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39056421/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240728041101&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 26:ehae446. doi: 10.1093/eurheartj/ehae446. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39056421/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240728041101&v=2.18.0.post9+e462414">39056421</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae446>10.1093/eurheartj/ehae446</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39056421</guid>
<pubDate>Fri, 26 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Giovanna Liuzzo</dc:creator>
<dc:creator>Carlo Patrono</dc:creator>
<dc:date>2024-07-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: apolipoprotein A1 is not an adequate shield against early vascular events after acute myocardial infarction</dc:title>
<dc:identifier>pmid:39056421</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae446</dc:identifier>
</item>
<item>
<title>Polygenic scores in real-world cardiovascular risk prediction: the path forward for assessing worth?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39056297/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240728041101&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 26:ehae442. doi: 10.1093/eurheartj/ehae442. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39056297/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240728041101&v=2.18.0.post9+e462414">39056297</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae442>10.1093/eurheartj/ehae442</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39056297</guid>
<pubDate>Fri, 26 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Virimchi Pillutla</dc:creator>
<dc:creator>Krishna G Aragam</dc:creator>
<dc:date>2024-07-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Polygenic scores in real-world cardiovascular risk prediction: the path forward for assessing worth?</dc:title>
<dc:identifier>pmid:39056297</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae442</dc:identifier>
</item>
<item>
<title>Coronary bypass surgery for multivessel disease after percutaneous coronary intervention in acute coronary syndromes: why, for whom, how early?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39056269/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240728041101&amp;v=2.18.0.post9+e462414
      <description>Multivessel coronary artery disease is present in ∼50% of patients with acute coronary syndrome and, compared with single-vessel disease, entails a higher risk of new ischaemic events and a worse prognosis. Randomized controlled trials have shown the superiority of 'complete revascularization' over culprit lesion-only treatment. Trials, however, only included patients treated with percutaneous coronary intervention (PCI), and evidence regarding complete revascularization with coronary artery...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 26:ehae413. doi: 10.1093/eurheartj/ehae413. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Multivessel coronary artery disease is present in ∼50% of patients with acute coronary syndrome and, compared with single-vessel disease, entails a higher risk of new ischaemic events and a worse prognosis. Randomized controlled trials have shown the superiority of 'complete revascularization' over culprit lesion-only treatment. Trials, however, only included patients treated with percutaneous coronary intervention (PCI), and evidence regarding complete revascularization with coronary artery bypass graft (CABG) surgery after culprit lesion-only PCI ('hybrid revascularization') is lacking. The CABG after PCI is an open, non-negligible therapeutic option, for patients with non-culprit left main and/or left anterior descending coronary artery disease where evidence in chronic coronary syndrome patients points in several cases to a preference of CABG over PCI. This valuable but poorly studied 'PCI first-CABG later' option presents, however, relevant challenges, mostly in the need of interrupting post-stenting dual antiplatelet therapy (DAPT) for surgery to prevent excess bleeding. Depending on patients' clinical characteristics and coronary anatomical features, either deferring surgery after a safe interruption of DAPT or bridging DAPT interruption with intravenous short-acting antithrombotic agents appears to be a suitable option. Off-pump minimally invasive surgical revascularization, associated with less operative bleeding than open-chest surgery, may be an adjunctive strategy when revascularization cannot be safely deferred and DAPT is not interrupted. Here, the rationale, patient selection, optimal timing, and adjunctive strategies are reviewed for an ideal approach to hybrid revascularization in post-acute coronary syndrome patients to support physicians' choices in a case-by-case patient-tailored approach.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39056269/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240728041101&v=2.18.0.post9+e462414">39056269</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae413>10.1093/eurheartj/ehae413</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39056269</guid>
<pubDate>Fri, 26 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Laura Besola</dc:creator>
<dc:creator>Andrea Colli</dc:creator>
<dc:creator>Raffaele De Caterina</dc:creator>
<dc:date>2024-07-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Coronary bypass surgery for multivessel disease after percutaneous coronary intervention in acute coronary syndromes: why, for whom, how early?</dc:title>
<dc:identifier>pmid:39056269</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae413</dc:identifier>
</item>
<item>
<title>The puzzle of antiplatelet therapy in ACS: ticagrelor monotherapy is another missing piece</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39056261/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240728041101&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 26:ehae440. doi: 10.1093/eurheartj/ehae440. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39056261/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240728041101&v=2.18.0.post9+e462414">39056261</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae440>10.1093/eurheartj/ehae440</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39056261</guid>
<pubDate>Fri, 26 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Wout W A van den Broek</dc:creator>
<dc:creator>Jurriën M Ten Berg</dc:creator>
<dc:date>2024-07-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The puzzle of antiplatelet therapy in ACS: ticagrelor monotherapy is another missing piece</dc:title>
<dc:identifier>pmid:39056261</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae440</dc:identifier>
</item>
<item>
<title>STEPping down diuretic therapy with semaglutide in obesity-related heart failure with preserved ejection fraction: decongestion or disease modification?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39056260/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240728041101&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 26:ehae410. doi: 10.1093/eurheartj/ehae410. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39056260/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240728041101&v=2.18.0.post9+e462414">39056260</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae410>10.1093/eurheartj/ehae410</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39056260</guid>
<pubDate>Fri, 26 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>John W Ostrominski</dc:creator>
<dc:creator>Safia Chatur</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:date>2024-07-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>STEPping down diuretic therapy with semaglutide in obesity-related heart failure with preserved ejection fraction: decongestion or disease modification?</dc:title>
<dc:identifier>pmid:39056260</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae410</dc:identifier>
</item>
<item>
<title>Acute coronary occlusion during valve-in-valve TAVI-a shortcut to successful prevention</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39056259/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240728041101&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 26:ehae439. doi: 10.1093/eurheartj/ehae439. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39056259/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240728041101&v=2.18.0.post9+e462414">39056259</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae439>10.1093/eurheartj/ehae439</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39056259</guid>
<pubDate>Fri, 26 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Bernard D Prendergast</dc:creator>
<dc:creator>Tiffany Patterson</dc:creator>
<dc:creator>Simon Redwood</dc:creator>
<dc:date>2024-07-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Acute coronary occlusion during valve-in-valve TAVI-a shortcut to successful prevention</dc:title>
<dc:identifier>pmid:39056259</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae439</dc:identifier>
</item>
<item>
<title>Lysozyme 1 Inflamed CCR2&lt;sup>;+&lt;/sup>; Macrophages Promote Obesity-Induced Cardiac Dysfunction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39056179/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240728041101&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our findings suggest that lysozyme 1 may represent a potential target for the diagnosis of obesity-induced inflammation and the treatment of obesity-induced heart disease.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jul 26. doi: 10.1161/CIRCRESAHA.124.324106. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Macrophages are key players in obesity-associated cardiovascular diseases, which are marked by inflammatory and immune alterations. However, the pathophysiological mechanisms underlying macrophage's role in obesity-induced cardiac inflammation are incompletely understood. Our study aimed to identify the key macrophage population involved in obesity-induced cardiac dysfunction and investigate the molecular mechanism that contributes to the inflammatory response.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS AND RESULTS: Though analyzing in-depth cardiac macrophage clusters identified by single macrophage RNA-sequencing, we find that the <i>Ccr2</i> cluster undergoes a functional transition from homeostatic maintenance to proinflammation. Our data highlight specific changes in macrophage behavior during cardiac dysfunction under metabolic challenge. Consistently, inducible ablation of CCR2<sup>+</sup>CX3CR1<sup>+</sup> macrophages by a dual recombinase-based lineage-tracing approach or selective deletion of macrophage C-C chemokine receptor 2 (CCR2) prevents obesity-induced cardiac dysfunction. At the mechanistic level, we demonstrate that the obesity-induced functional shift of CCR2-expressing macrophages is mediated by the CCR2/ATF3/lysozyme 1/NF-κB (nuclear factor kappa B) signaling. Finally, we uncover a noncanonical role for lysozyme 1 as a transcription activator, binding to the <i>RelA</i> promoter, driving NF-κB signaling, and strongly promoting inflammation and cardiac dysfunction in obesity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our findings suggest that lysozyme 1 may represent a potential target for the diagnosis of obesity-induced inflammation and the treatment of obesity-induced heart disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39056179/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240728041101&v=2.18.0.post9+e462414">39056179</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324106>10.1161/CIRCRESAHA.124.324106</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39056179</guid>
<pubDate>Fri, 26 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Lai Zhang</dc:creator>
<dc:creator>Huian Han</dc:creator>
<dc:creator>Andi Xu</dc:creator>
<dc:creator>Adwait Sathe</dc:creator>
<dc:creator>Siying Fu</dc:creator>
<dc:creator>Jiaqi Zhao</dc:creator>
<dc:creator>Wenhan Cai</dc:creator>
<dc:creator>Yaqing Yang</dc:creator>
<dc:creator>Jinting Liu</dc:creator>
<dc:creator>Hui Bai</dc:creator>
<dc:creator>Jingjing Ben</dc:creator>
<dc:creator>Xudong Zhu</dc:creator>
<dc:creator>Xiaoyu Li</dc:creator>
<dc:creator>Qing Yang</dc:creator>
<dc:creator>Zidun Wang</dc:creator>
<dc:creator>Yayun Gu</dc:creator>
<dc:creator>Chao Xing</dc:creator>
<dc:creator>Gabriele G Schiattarella</dc:creator>
<dc:creator>Steven Yan Cheng</dc:creator>
<dc:creator>Hanwen Zhang</dc:creator>
<dc:creator>Qi Chen</dc:creator>
<dc:date>2024-07-26</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Lysozyme 1 Inflamed CCR2&lt;sup>;+&lt;/sup>; Macrophages Promote Obesity-Induced Cardiac Dysfunction</dc:title>
<dc:identifier>pmid:39056179</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324106</dc:identifier>
</item>
<item>
<title>RNA Helicase DDX5 Maintains Cardiac Function by Regulating &lt;em>;CamkIIδ&lt;/em>; Alternative Splicing</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39056171/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240728041101&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These findings reveal a role for DDX5 in maintaining calcium homeostasis and cardiac function by regulating alternative splicing in cardiomyocytes, identifying the DDX5 as a potential target for therapeutic intervention in HF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 26. doi: 10.1161/CIRCULATIONAHA.123.064774. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Heart failure (HF) is a leading cause of morbidity and mortality worldwide. RNA-binding proteins are identified as regulators of cardiac disease; DDX5 (dead-box helicase 5) is a master regulator of many RNA processes, although its function in heart physiology remains unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We assessed DDX5 expression in human failing hearts and a mouse HF model. To study the function of DDX5 in heart, we engineered cardiomyocyte-specific <i>Ddx5</i> knockout mice. We overexpressed DDX5 in cardiomyocytes using adeno-associated virus serotype 9 and performed transverse aortic constriction to establish the murine HF model. The mechanisms underlined were subsequently investigated using immunoprecipitation-mass spectrometry, RNA-sequencing, alternative splicing analysis, and RNA immunoprecipitation sequencing.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We screened transcriptome databases of murine HF and human dilated cardiomyopathy samples and found that DDX5 was significantly downregulated in both. Cardiomyocyte-specific deletion of <i>Ddx5</i> resulted in HF with reduced cardiac function, an enlarged heart chamber, and increased fibrosis in mice. DDX5 overexpression improved cardiac function and protected against adverse cardiac remodeling in mice with transverse aortic constriction-induced HF. Furthermore, proteomics revealed that DDX5 is involved in RNA splicing in cardiomyocytes. We found that DDX5 regulated the aberrant splicing of Ca<sup>2+</sup>/calmodulin-dependent protein kinase IIδ (<i>CamkIIδ</i>), thus preventing the production of CaMKIIδA, which phosphorylates L-type calcium channel by serine residues of Cacna1c, leading to impaired Ca<sup>2+</sup> homeostasis. In line with this, we found increased intracellular Ca<sup>2+</sup> transients and increased sarcoplasmic reticulum Ca<sup>2+</sup> content in DDX5-depleted cardiomyocytes. Using adeno-associated virus serotype 9 knockdown of CaMKIIδA partially rescued the cardiac dysfunction and HF in <i>Ddx5</i> knockout mice.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These findings reveal a role for DDX5 in maintaining calcium homeostasis and cardiac function by regulating alternative splicing in cardiomyocytes, identifying the DDX5 as a potential target for therapeutic intervention in HF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39056171/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240728041101&v=2.18.0.post9+e462414">39056171</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064774>10.1161/CIRCULATIONAHA.123.064774</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39056171</guid>
<pubDate>Fri, 26 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Kangni Jia</dc:creator>
<dc:creator>Haomai Cheng</dc:creator>
<dc:creator>Wenqi Ma</dc:creator>
<dc:creator>Lingfang Zhuang</dc:creator>
<dc:creator>Hao Li</dc:creator>
<dc:creator>Zhigang Li</dc:creator>
<dc:creator>Ziyang Wang</dc:creator>
<dc:creator>Hang Sun</dc:creator>
<dc:creator>Yuke Cui</dc:creator>
<dc:creator>Hang Zhang</dc:creator>
<dc:creator>Hongyang Xie</dc:creator>
<dc:creator>Lei Yi</dc:creator>
<dc:creator>Zhiyong Chen</dc:creator>
<dc:creator>Motoaki Sano</dc:creator>
<dc:creator>Keiichi Fukuda</dc:creator>
<dc:creator>Lin Lu</dc:creator>
<dc:creator>Jun Pu</dc:creator>
<dc:creator>Yan Zhang</dc:creator>
<dc:creator>Ling Gao</dc:creator>
<dc:creator>Ruiyan Zhang</dc:creator>
<dc:creator>Xiaoxiang Yan</dc:creator>
<dc:date>2024-07-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>RNA Helicase DDX5 Maintains Cardiac Function by Regulating &lt;em>;CamkIIδ&lt;/em>; Alternative Splicing</dc:title>
<dc:identifier>pmid:39056171</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.064774</dc:identifier>
</item>





























</channel>
</rss>